266 related articles for article (PubMed ID: 28633036)
21. The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
McCarthy PL; Einsele H; Attal M; Giralt S
Expert Rev Hematol; 2014 Feb; 7(1):55-66. PubMed ID: 24471885
[TBL] [Abstract][Full Text] [Related]
22. Current and emerging treatments for multiple myeloma.
Schwartz RN; Vozniak M
J Manag Care Pharm; 2008 Sep; 14(7 Suppl):12-9. PubMed ID: 18774881
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy strategies for multiple myeloma: the present and the future.
Locke FL; Nishihori T; Alsina M; Kharfan-Dabaja MA
Immunotherapy; 2013 Sep; 5(9):1005-20. PubMed ID: 23998734
[TBL] [Abstract][Full Text] [Related]
24. Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma.
Gassiot S; Motlló C; Llombart I; Morgades M; González Y; Garcia-Caro M; Ribera JM; Oriol A
Eur J Haematol; 2017 Jun; 98(6):569-576. PubMed ID: 28208219
[TBL] [Abstract][Full Text] [Related]
25. Optimal treatment strategies in myeloma: An argument against maintenance therapy after autologous stem cell transplantation.
Richter J; Biran N; Vesole D; Siegel D
Semin Oncol; 2016 Dec; 43(6):714-717. PubMed ID: 28061995
[TBL] [Abstract][Full Text] [Related]
26. Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma.
Rafei H; Haroun F; Tabbara IA
Am J Clin Oncol; 2019 Mar; 42(3):317-329. PubMed ID: 30557165
[TBL] [Abstract][Full Text] [Related]
27. Multiple myeloma: is a shift toward continuous therapy needed to move forward?
Guglielmelli T; Palumbo A
Expert Rev Hematol; 2015 Jun; 8(3):253-6. PubMed ID: 25582032
[TBL] [Abstract][Full Text] [Related]
28. The current status of hematopoietic stem cell transplantation for multiple myeloma.
Bensinger WI
Clin Adv Hematol Oncol; 2004 Jan; 2(1):46-52. PubMed ID: 16163159
[TBL] [Abstract][Full Text] [Related]
29. Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.
Sahebi F; Iacobelli S; Biezen AV; Volin L; Dreger P; Michallet M; Ljungman PT; de Witte T; Henseler A; Schaap NP; López-Corral L; Poire X; Passweg J; Hamljadi RM; Thomas SH; Schonland S; Gahrton G; Morris C; KrÖger N; Garderet L
Bone Marrow Transplant; 2015 Jun; 50(6):802-7. PubMed ID: 25798673
[TBL] [Abstract][Full Text] [Related]
30. [Induction therapy of transplant-eligible patients in multiple myeloma].
Konishi J; Sunami K
Nihon Rinsho; 2015 Jan; 73(1):90-4. PubMed ID: 25626311
[TBL] [Abstract][Full Text] [Related]
31. Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.
Maybury B; Cook G; Pratt G; Yong K; Ramasamy K
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1926-1937. PubMed ID: 27288955
[TBL] [Abstract][Full Text] [Related]
32. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
33. Multiple myeloma.
Röllig C; Knop S; Bornhäuser M
Lancet; 2015 May; 385(9983):2197-208. PubMed ID: 25540889
[TBL] [Abstract][Full Text] [Related]
34. Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.
Ahmad I; LeBlanc R; Cohen S; Lachance S; Kiss T; Sauvageau G; Roy DC; Busque L; Delisle JS; Bambace N; Bernard L; Sabry W; Roy J
Bone Marrow Transplant; 2016 Apr; 51(4):529-35. PubMed ID: 26691426
[TBL] [Abstract][Full Text] [Related]
35. A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?
Green DJ; Bensinger WI
Curr Hematol Malig Rep; 2017 Feb; 12(1):61-67. PubMed ID: 28144893
[TBL] [Abstract][Full Text] [Related]
36. Improving induction therapy in multiple myeloma.
Nooka A; Gleason C; Lonial S
Curr Hematol Malig Rep; 2010 Jul; 5(3):119-28. PubMed ID: 20449692
[TBL] [Abstract][Full Text] [Related]
37. Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group.
Quach H; Joshua D; Ho J; Szer J; Spencer A; Harrison S; Mollee P; Roberts A; Horvath N; Talaulikar D; To B; Zannettino A; Brown R; Catley L; Augustson B; Jaksic W; Gibson J; Prince HM
Intern Med J; 2015 Mar; 45(3):335-43. PubMed ID: 25735577
[TBL] [Abstract][Full Text] [Related]
38. Initial treatment of transplant-eligible patients in multiple myeloma.
Rosiñol L; Kumar S; Moreau P; Cavo M
Expert Rev Hematol; 2014 Feb; 7(1):43-53. PubMed ID: 24392968
[TBL] [Abstract][Full Text] [Related]
39. The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Bensinger WI
Leukemia; 2006 Oct; 20(10):1683-9. PubMed ID: 16888617
[TBL] [Abstract][Full Text] [Related]
40. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
Voorhees PM; Usmani SZ
Clin Adv Hematol Oncol; 2016 Sep; 14(9):719-28. PubMed ID: 27673290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
